Bisphosphonates bind calcium in the gut when taken together, preventing both bisphosphonate absorption AND calcium absorption. Must be taken separately. Additionally, bisphosphonates suppress osteoclast activity, trapping old bone mineral in a way that paradoxically can reduce calcium availability.
FDA prescribing information: bisphosphonates must be taken 30–60 minutes before any calcium-containing food or supplements. Hypocalcemia is a documented adverse event, particularly with IV bisphosphonates. Cases of severe hypocalcemia in vitamin D-deficient patients.
Hypocalcemia, muscle cramps, tetany, paresthesia, cardiac arrhythmia
Calcium 600–800mg from diet and supplement — taken at a DIFFERENT time than bisphosphonate (evening is ideal). Vitamin D3 is equally critical — bisphosphonates are ineffective in vitamin D-deficient patients.
View on Fullscript: Thorne Vitamin D/K2 Liquid (take separately from bisphosphonate)Discuss with your physician before adjusting supplementation. This is educational content, not medical advice.
Bisphosphonates are clinically ineffective without adequate Vitamin D. The drugs reduce bone resorption, but new bone formation requires D3 for calcium deposition. Hypovitaminosis D negates bisphosphonate benefit and dramatically increases hypocalcemia risk.
Adami et al. (Osteoporos Int, 2009) — 64% of bisphosphonate patients are Vitamin D deficient. Holick et al. (NEJM, 2007) — D3 deficiency renders bisphosphonates clinically ineffective. All major osteoporosis guidelines mandate concurrent D3.
Bisphosphonate treatment failure, persistent bone loss, hypocalcemia, muscle weakness
Test 25(OH)D before starting. Supplement 2,000–5,000 IU D3 + K2 to achieve 50–80 ng/mL. This is not optional — it is required for the drug to work.
View on Fullscript: Thorne Vitamin D/K2 LiquidDiscuss with your physician before adjusting supplementation. This is educational content, not medical advice.
Like calcium, magnesium binds bisphosphonates in the GI tract, reducing absorption of both. Long-term bisphosphonate use with impaired magnesium absorption contributes to the muscle weakness and jaw osteonecrosis risk profile.
Bisphosphonate-induced osteonecrosis of the jaw (ONJ) involves impaired bone remodeling — magnesium is required for proper osteoblast function. Magnesium deficiency impairs hydroxyapatite crystal formation in new bone.
Muscle weakness, increased ONJ risk theoretically, poor bone quality despite density preservation
Magnesium glycinate 300–400mg daily — taken at a different time than bisphosphonate (evening with calcium is appropriate).
View on Fullscript: Thorne Magnesium BisglycinateDiscuss with your physician before adjusting supplementation. This is educational content, not medical advice.
Taking Bisphosphonates? Build Your Replenishment Stack.
Our clinical intake tool accounts for your medications, health goals, and risk factors — and outputs a personalized supplement protocol rated against published clinical trials.
Open the Full Tool Suite